FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial

BACKGROUND: Currently, assessment of candidate pharmacotherapies in patients with non-alcoholic steatohepatitis (NASH) involves invasive liver biopsy. Non-invasive scores, such as the FibroScan-aspartate aminotransferase (FAST) score, are used to identify candidates for therapy, but their ability to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wai-Sun Wong, Vincent, Anstee, Quentin M., Nitze, Louise M., Geerts, Anja, George, Jacob, Nolasco, Victor, Kjær, Mette S., Ladelund, Steen, Newsome, Philip N., Ratziu, Vlad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696384/
http://dx.doi.org/10.1016/j.eclinm.2023.102310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696384/
http://dx.doi.org/10.1016/j.eclinm.2023.102310

Ejemplares similares